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Summary
Antibodies protect against homologous Dengue virus (DENV) infection but can precipitate severe
dengue by promoting heterotypic virus entry via Fcγ receptors (FcγR). We immortalized memory
B cells from individuals after primary or secondary infection and analyzed anti-DENV
monoclonal antibodies (mAbs) thus generated. MAbs to envelope (E) protein domain III (DIII)
were either serotype specific or cross-reactive and potently neutralized DENV infection. DI/DII-
or viral membrane protein prM-reactive mAbs neutralized poorly and showed broad cross-
reactivity with the four DENV serotypes. All mAbs enhanced infection at subneutralizing
concentrations. Three mAbs targeting distinct epitopes on the four DENV serotypes and
engineered to prevent FcγR binding did not enhance infection and neutralized DENV in vitro and
in vivo as postexposure therapy in a mouse model of lethal DENV infection. Our findings reveal
an unexpected degree of cross-reactivity in human antibodies against DENV and illustrate the
potential for an antibody-based therapy to control severe dengue.
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Dengue virus (DENV) is a mosquito-borne Flavivirus responsible for tens of millions of
human cases of dengue annually, including 500,000 hospitalizations and 20,000 deaths
(Gibbons and Vaughn, 2002), with an economic burden rivaling that of malaria. A primary
infection is believed to provide effective, durable and possibly life-long protection against
re-infection with the same serotype, but only short-term protection against other serotypes
(Rothman, 2004). Classical epidemiologic studies suggested that immunity to one of the
four DENV serotypes can increase disease severity upon subsequent challenge with a
different serotype leading, in some cases, to severe dengue, a disease characterized by
plasma leakage and hemorrhagic manifestations (Halstead, 1970). Poorly neutralizing cross-
reactive antibodies raised in response to a previous serotype are believed to contribute to
pathogenesis of severe dengue by promoting virus entry via Fcγ receptors (FcγR) and
infection of myeloid cells (Halstead, 2003), leading to antibody-dependent enhancement
(ADE) of infection. The role of antibodies in severe dengue is supported by epidemiological
studies showing that infants with waning levels of maternal antibodies (age 6–9 months) are
most vulnerable to severe DENV disease (Halstead et al., 2002; Nguyen et al., 2004), and
that serum from these infants enhances DENV infection in vitro (Chau et al., 2008; Kliks et
al., 1988). The difficulty of balancing immunity to the four serotypes and minimizing
incomplete response and the risk of ADE are major hurdles in the development of a
tetravalent vaccine against DENV (Whitehead et al., 2007).
The 10.7 Kb RNA genome of DENV encodes three structural proteins, the capsid protein
(C), a membrane-associated protein (prM), and an envelope protein (E), and seven non-
structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). The E protein is
structurally conserved among flaviviruses and consists of three distinct domains. Domain I
(DI) participates in the conformational changes required for viral entry and nucleocapsid
escape from the endosomal compartment, domain II (DII) contains the fusion loop, and
domain III (DIII) has been suggested to bind cellular receptors (Bhardwaj et al., 2001; Chin
et al., 2007; Chu et al., 2005; Rey et al., 1995). Partially mature virions also express varying
levels of prM protein on their surface, which is normally cleaved by a furin-like cellular
protease to generate the mature virion (Stadler et al., 1997).
The most potent neutralizing antibodies against DENV, or other flaviviruses such as West
Nile Virus (WNV), bind to DIII and have been shown in some cases to be effective as
passive prophylaxis or therapy in rodents (Beasley and Barrett, 2002; Goncalvez et al.,
2008; Gromowski et al., 2008; Kaufman et al., 1987; Oliphant et al., 2005; Sanchez et al.,
2005; Shrestha et al., 2010; Sukupolvi-Petty et al., 2007). DIII-reactive antibodies produced
by mice immunized with virus and boosted with recombinant E protein are largely serotype-
specific and do not neutralize all the genotypes within a given serotype (Shrestha et al.,
2010). The role of antibodies to DI/DII is less clear as they tend to be more cross-reactive
and less potent in neutralization (Crill and Chang, 2004; Goncalvez et al., 2004; Oliphant et
al., 2006). Antibodies to prM generally have poor neutralizing and enhancing activity
(Falconar, 1999; Huang et al., 2006), although recent studies suggest that some anti-prM
mAbs can augment infectivity of poorly infectious immature virions (Rodenhuis-Zybert et
al., 2010). Antibodies against NS1, a secreted non-structural glycoprotein that is absent from
the virion but expressed on the cell surface, can also protect against infection in vivo,
through FcγR-dependent and -independent mechanisms (Chung et al., 2006), or possibly
contribute to pathogenesis (Falconar, 2007; Lin et al., 2008).
Our current knowledge of the human antibody response to DENV is mostly based on
serological studies. In this study, we used an improved method of memory B cell
immortalization (Traggiai et al., 2004) combined with a broad screening approach to isolate
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a large panel of DENV-reactive mAbs from human donors. MAbs that bound to DIII of the
E protein potently neutralized DENV infection, although they also showed enhancing
activity at lower concentrations. In contrast mAbs that bound to DI/DII of E protein or prM
neutralized poorly, yet potently enhanced infection of FcγR-bearing cells. Surprisingly,
some of the human DIII-specific mAbs and all DI/DII-specific mAbs isolated from
secondary infection showed a broad pattern of cross-reactivity with the four DENV
serotypes. Based on an improved understanding of the functional humoral response against
DENV, we produced a cocktail of three variant recombinant mAbs that neutralized all four
DENV serotypes without causing immune enhancement in vitro and in vivo.
Results
High frequency of DENV-specific memory B cells in immune donors
Blood samples were collected from donors at different time points after diagnosis of either
primary (Donor 7, Donor 13 and Donor 76) or secondary (Donor 12 and Donor 92) DENV
infection. IgG+ memory B cells isolated from frozen PBMC were immortalized with EBV
and CpG in multiple replicate wells as previously described (Traggiai et al., 2004). Culture
supernatants were collected after two weeks and analyzed by staining of fixed and
permeabilized C6/36 mosquito cells infected with DENV or by ELISA using recombinant E
protein from DENV-1, DENV-2 and DENV-4, or lysates of DENV-infected cells (Table 1).
The frequency of IgG+ memory B cells reactive against DENV-infected cells, calculated
from the number of positive cultures and the number of input cells after corrections for the
efficiency of B cell immortalization, was high in all donors, ranging from 5.4% to 16% of
IgG+ memory B cells. In the three donors that were screened using E protein, the frequency
of E-reactive IgG+ memory B cells ranged from 1.5% to 3.2%. These findings indicate that
DENV-immune donors maintain a very large pool of memory B cells reactive against
DENV proteins, even several years after infection.
Because the E protein, and in particular DIII, is the main target of neutralizing anti-WNV
antibodies in mice (Oliphant et al., 2007), we performed a large screen to gain insights into
the domain specificity and cross-reactivity of E-specific antibodies isolated from Donor 13
(primary DENV-2) and Donor 12 (secondary DENV-1). Eighteen out of 152 antibodies
from Donor 13 bound to DIII of DENV-2. Of these, 13 were serotype specific, 1 cross-
reacted with DENV-2, −3 and −4, and 4 cross-reacted with all four DENV serotypes. In the
case of Donor 12, a large fraction of E-reactive antibodies bound to DIII (138 out of 313).
Of these, 44 were specific for DIII of DENV-1, whereas the remaining 94 were cross-
reactive with two, three or all four DENV serotypes (16, 15, and 63, respectively). Taken
together, these findings indicate that the human antibody response to DIII of DENV E
protein elicited by natural infection comprises serotype specific as well as broadly cross-
reactive antibodies.
Isolation of human monoclonal antibodies to DENV
In order to better characterize the human antibody response to DENV, we isolated B cell
clones from several independent cultures and characterized 70 DENV-reactive monoclonal
antibodies (mAbs) (68 IgG1, either κ or λ, 1 IgG3, λ, and 1 IgG4, λ). All DENV-reactive
mAbs bound to one or more DENV serotypes, as shown by staining of Vero cells infected
with DENV-1, DENV-2, DENV-3, or DENV-4 (see examples in Figure 1A). Specificity and
cross-reactivity were assessed using binding assays (ELISA with recombinant E, NS1 and
NS3 proteins, staining of yeast displaying DI/DII or DIII, or Western blot of infected cell
lysates) (see examples in Figure 1B–D). Mabs were also characterized using functional
assays (neutralization or enhancement of infection by DENV vaccine strains using flow
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cytometry assays with Vero and K562 cells, respectively (Kraus et al., 2007; Littaua et al.,
1990)) (see examples in Figure 1E, F).
Serotype-specific and cross-reactive mAbs to DIII of E-protein
Of the 70 DENV-reactive mAbs isolated, 13 mapped to DIII of E protein and of these, 5
were serotype-specific, whereas 8 were cross-reactive with two, three or even all four
DENV serotypes (Table 2). Of the five serotype-specific mAbs, three (DV3.7, DV25.5, and
DV470.12) potently neutralized infection of Vero cells by either DENV-1 or DENV-2
vaccine strains, with EC50 values in the low ng/ml range, whereas two mAbs (DV1.6 and
DV14.5) showed decreased potency against DENV-2, suggesting that they may represent
low affinity antibodies or may target private epitopes within DENV-2. Of the 8 cross-
reactive mAbs, two (DV63.1 and DV55.1) potently neutralized DENV-1 and DENV-3,
whereas mAb DV87.1 potently neutralized DENV-1, DENV-2 and DENV-3. Strikingly, the
cross-reactive mAbs DV63.1 and DV87.1 neutralized infection in the same range of
concentrations as observed for serotype-specific mAbs (Table 2). Finally, four mAbs bound
all serotypes by ELISA and of these, two neutralized, albeit with low potency, all serotypes
(DV21.5 and DV257.13), whereas the remaining mAbs showed a more restricted pattern of
neutralization.
Consistent with what is known about the stoichiometric relationship between neutralization
and enhancement (Pierson et al., 2007), DIII-specific mAbs also enhanced infection of K562
cells over a given range of concentrations with the same serotype specificity as shown in the
neutralization assay (Table 2).
These results indicate that it is possible to isolate DIII-reactive human mAbs that potently
neutralize infection of two or more DENV serotypes.
DI/DII-specific mAbs from secondary DENV infection cross-react with all four DENV
serotypes
Of the 70 DENV-reactive mAbs, 34 mapped to DI/DII of E protein (Table 3). Of these, 8
were serotype-specific, 1 cross-reacted with DENV-1 and DENV-2, and 25 cross-reacted
with all four DENV serotypes. When compared to DIII-specific mAbs, the DI/DII-specific
mAbs showed in general a 10-50-fold lower potency of neutralization and enhanced
infection over a wide range of concentrations (Table 3). Of interest, whereas DI/II-reactive
mAbs isolated from primary infections (Donors 7, 13 and 76) were mostly serotype-specific,
all DI/DII-reactive mAbs isolated from secondary infection (Donors 12 and 92) neutralized
and enhanced infection by all four DENV serotypes. These findings suggest that broadly
cross-reactive DI/DII-specific memory B cells may be selected during the course of
secondary DENV infection.
Some of the broadly reactive DI/DII-specific mAbs were analyzed for reactivity against
West Nile virus (WNV). Seven mAbs stained yeast cells expressing DI/DII of WNV E
protein (Table S1). Using site-directed mutants in DII that had been previously generated
(Crill and Chang, 2004; Oliphant et al., 2006), we localized binding of three mAbs to the
fusion loop peptide at the tip of DII (W101R, G106E) and of a fourth mAb to the W233F
residue on the dimmer interface of DII. The binding of the other three cross-reactive mAbs
was not affected by these mutations, indicating that they map to DI/DII but outside of the
fusion loop region.
Finally, 4 mAbs (DV66.1, DV57.4, DV61.2, and DV77.5), which were selected for binding
to DENV-infected cells, did not bind to recombinant E proteins in ELISA but bound to E
protein in Western blot (Figure 1B). DV66.1 and DV57.4 neutralized one and three DENV
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serotypes, respectively, whereas DV61.2 and DV77.5 did not neutralize DENV infection at
the highest concentration tested. However, all 4 mAbs showed ADE activity (Table 3).
Human monoclonal antibodies to prM and to non-structural proteins
We next characterized 19 mAbs that stained DENV-infected cells but did not recognize E
protein. Six mAbs reacted with a band in Western blot corresponding to prM, as indicated
by the mouse anti-prM mAb 2H2 used as control (Falconar, 1999) (Figure 1C). As
independent verification, we also performed cross-competition experiments and found that
the anti-prM mAbs DV64.3, DV27.2, and DV69.6 inhibited binding of 2H2, suggesting that
they may recognize the same or overlapping epitopes, whereas DV52.1, DV75.9, and
DV62.5 did not compete with 2H2 and may recognize distinct epitopes (data not shown).
Surprisingly, five of these mAbs stained a band corresponding to E-prM protein and three of
them (DV64.3, DV52.1 and DV62.5) also recognized a band corresponding to the E protein.
The reactivity of mAbs with both prM and E suggests a quaternary epitope with shared sites
on the heterodimeric prM-E protein; a similar finding has been reported for mouse
antibodies (Falconar, 1999; Gould et al., 1985; Puttikhunt et al., 2008). With the single
exception of mAb DV52.1, all the prM-specific mAbs were broadly cross-reactive as they
bound to cells infected with all four DENV serotypes (Table 4). All prM-reactive mAbs
enhanced DENV infection over a broad range of concentrations whereas only three
neutralized infection with low potency (Table 4). Thus, consistent with a recent study
(Dejnirattisai et al., 2010), the prM-specific mAbs were highly cross-reactive among the
DENV serotypes and potently promoted ADE.
Eleven mAbs were mapped to NS1 or NS3 protein, as determined by ELISA with
recombinant proteins and Western blot (Figure 1D and data not shown). Five NS1-specific
mAbs cross-reacted with all DENV serotypes, whereas the remaining two mAbs reacted
with DENV-1 and DENV-3, and the four NS3-specific mAbs were all DENV-3-specific
(Table 4). Finally, only one mAb (DV86.2) recognized the capsid protein (Table 4 and
Figure 1B). Another mAb (DV34.4) was not assigned to a specific protein, although it
showed high neutralizing activity against DENV-2 and, to a lower extent, DENV-4 (Table
4). This mAb likely recognizes a conformationally-sensitive epitope on E (e.g., hinge or
interface between domains of oligomers) as was observed recently with two human mAbs
against WNV (Vogt et al., 2009).
A broadly neutralizing antibody cocktail lacking enhancing activity
Given the availability of human mAbs that potently neutralized DENV infection, we set out
to develop a candidate antibody-based therapeutic for dengue consisting of a “cocktail” of
neutralizing mAbs. Ideally, this cocktail should: i) neutralize all DENV serotypes, ii) target
at least two non- overlapping epitopes on each virus in order to minimize selection of escape
mutants, and, iii) fail to enhance infection. We therefore selected two mAbs with potent and
complementary neutralizing activity: DV87.1 specific for DIII of DENV-1, −2 and −3 and
DV22.3 specific for DI/DII of DENV-4. As a complement we selected a DI/DII-specific
mAb (DV82.11) that neutralized with comparable efficiency all four DENV serotypes
(Figure 2A). Cross-competition experiments were consistent with the notion that the target
epitopes recognized by the three mAbs did not overlap (Figure S1). Thus, a cocktail of
DV87.1, DV22.3 and DV82.11 is expected to neutralize all DENV serotypes by targeting
two distinct sites on each virus.
Because the selected neutralizing mAbs also enhanced infection (Figure 2A), we generated
variants of DV87.1, DV22.3 and DV82.11 in which leucine residues at positions 1.3 and 1.2
of CH2 domain (according to the IMGT unique numbering for C-domain) were substituted
with alanine residues. This modification, also known as “LALA” mutation, abolishes
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antibody binding to FcγRI, FcγRII and FcγRIIIa (Hessell et al., 2007). The variant and
unmodified recombinant mAbs were expressed in HEK293T cells, and the purified mAbs
were compared for their capacity to neutralize and enhance infection by the four DENV
serotypes. As shown in Figure 2B, LALA variants retained the same neutralizing activity as
unmodified mAbs, but were completely devoid of enhancing activity. In addition, the LALA
cocktail, even at very low concentrations (DV82.11 = 2 µg/ml; DV87.1 = DV22.3 = 0.2 µg/
ml), blocked ADE induced by enhancing prM or DI/DII mAbs or immune serum (Figure
2C).
To determine whether the combination of LALA mAbs might achieve increased
neutralization we used a variable ratio approach (Zwick et al., 2001). The concentration of
one mAb was varied in the presence of a fixed amount of a second mAb (added at a weakly
neutralizing concentration) and the titration curves of the first mAb alone or in combination
were compared. The EC90 values shown in Table S2 indicate a two- to fourfold increase in
neutralization potency, consistent with a modest additive effect.
Taken together, the above results suggest that a cocktail of three LALA variant mAbs
targeting different epitopes on each virus can efficiently neutralize DENV infection, while
avoiding and actually preventing enhancement of DENV infection in vitro.
LALA variant mAbs do not enhance DENV infection and show therapeutic efficacy in vivo
To assess the ability of LALA variants to neutralize DENV in vivo, we utilized a recently-
described mouse model of DENV ADE in which sub-lethal infection is enhanced by passive
transfer of anti-DENV antibodies, leading to lethal disease characterized by plasma leakage,
elevated serum cytokines and thrombocytopenia (Balsitis et al., 2010; Zellweger et al.,
2010), all features associated with severe dengue in humans. Unmodified or LALA variant
mAbs were transferred into AG129 mice 24 hours prior to a sub-lethal infection with
DENV-2 strain D2S10. Whereas mice receiving 5 µg of the mouse mAb 4G2 (pan-
flavivirus, E DI/DII-specific), developed an enhanced, lethal D2S10 infection, mice
receiving 1 or 5 µg of LALA mAb variants did not succumb to infection (Figure 3A; 1 or 5
µg DV87.1, LALA p<0.0253; 1 or 5 µg DV82.11 LALA, p<0.0455 as compared to 5 µg
4G2) or show signs of illness. In contrast, with one exception, all of the mice pretreated with
1 or 5 µg unmodified mAbs DV87.1 and DV82.11 showed enhanced lethal DENV infection,
whereas 5 of 6 mice receiving PBS alone survived infection (Figure 3A). The ability of the
unmodified mAbs to enhance DENV in mice was not affected by differences in the
interaction between the human mAbs and the murine Fcγ. Indeed, chimeric mAbs in which
the human constant region (hinge, CH2 and CH3 domains) was replaced with the
homologous murine Igγ2a constant region enhanced DENV infection comparably in vitro
and in vivo (data not shown).
To determine whether survival associated with transfer of the DV87.1 and DV82.11 LALA
variants was associated with reduced viral load, we measured the viral burden in serum and
tissues 3.5 days following D2S10 antibody-enhanced infection. Viremia and tissue viral load
measured in liver, small intestine and lymph node were significantly decreased in mice
receiving 5 µg of either LALA variant as compared to mice receiving 5 µg of the parent
unmodified mAbs (Figure S2, p<0.0495 for comparisons between mAb variants in the liver,
sera and lymph; in the small intestine, p<0.0369 for comparison between DV87.1 mAb
variants, and p<0.0463 between DV82.11 mAb variants).
To explore whether the LALA variants could serve as a possible therapy following DENV
infection, we administered 50 µg of the LALA variants or unmodified mAbs to mice 24
hours after infection with DENV-2 D2S10 under enhancing conditions (24 hours after
transfer of heterotypic anti-DENV-1 serum) (Balsitis et al., 2010). Mice receiving either the
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DV87.1 or DV82.11 LALA variant survived the normally lethal infection, whereas mice
receiving the unmodified parent mAbs succumbed to infection, as did mice receiving a non-
binding isotype control (DV22.3 LALA mAb that only recognizes DENV-4) or PBS (Figure
3B, DV87.1 LALA, p<0.0015; DV82.11 LALA, p<0.011 compared to DV22.3 LALA). In
summary, engineering of the LALA mutation on strongly neutralizing human mAbs
abrogates the capacity for ADE and confers a protective phenotype as a post-exposure
therapy in mice.
Discussion
In this study, we analyzed the memory B cell repertoires of individuals recovered from
primary or secondary DENV infection and characterized a large panel of mAbs specific for
structural and nonstructural proteins of DENV. The main findings are that immune donors
have a large repertoire of DENV-reactive memory B cells, even years after infection, and
that human E-specific as well as prM-specific mAbs isolated from these donors show
extensive cross-reactivity among the four DENV serotypes.
Previous studies using mouse mAbs established that DIII is the primary target of the most
potent neutralizing antibodies against flaviviruses, including WNV and DENV (Beasley and
Barrett, 2002; Gromowski and Barrett, 2007; Oliphant et al., 2005; Oliphant et al., 2007;
Sanchez et al., 2005; Sukupolvi-Petty et al., 2007). Our findings in humans agree with these
observations, as the isolated DIII-specific mAbs were indeed the most potent in neutralizing
DENV infection of Vero cells, with EC50 values in the low ng/ml range. However, whereas
mAbs produced by mice boosted with recombinant E protein could only neutralize a few
genotypes within a given serotype (Shrestha et al., 2010), the human mAbs to DIII showed
considerable breadth, with some mAbs being able to neutralize three or even all four DENV
serotypes. DI/DII-specific mAbs were less potent in viral neutralization and showed an even
higher degree of cross-reactivity. Strikingly, analysis performed on a large number of
culture supernatants showed that the fraction of DIII- and DI/DII-cross-reactive antibodies
was considerably higher in secondary infections. For instance 44.1% of supernatants
containing DIII-specific antibodies from Donor 12 (secondary DENV-1) cross-reacted with
two, three or four DENV serotypes whereas 100% of DI/DII-specific mAbs from Donor 92
(secondary DENV-2) cross-reacted with comparable EC50 values with all four DENV
serotypes.
Within the E-specific response, the relative proportion of DI/DII versus DIII antibodies
showed considerable variability in different donors. However, there was an overall
prevalence of DI/DII antibodies, which is consistent with serological studies with WNV and
DENV (Crill et al., 2009; Lai et al., 2008; Oliphant et al., 2007; Wahala et al., 2009).
Moreover, two recent studies described recombinant anti-WNV antibodies that were
generated after phage display screening of scFv (VH-VL) molecules (Gould et al., 2005;
Throsby et al., 2006), both of which observed immunodominance of DI/DII mAbs against
WNV E protein. For unclear reasons, it appears that DIII-specific antibodies are less
abundant in the human repertoire although they still may contribute significantly to
protection (Crill et al., 2009).
All neutralizing mAbs isolated in this study mediated ADE at sub-neutralizing
concentrations, whereas some E-specific mAbs and most prM-specific mAbs mediated ADE
but lacked neutralizing activity. A previous study reported the isolation of three human E
protein-specific mAbs, two of which showed enhancing but not neutralizing activity
(Schieffelin et al.). More recently, Screaton and co-workers showed that prM-specific mAbs
represent a major component of the human DENV-specific response and that these mAbs
are highly cross-reactive and, even at high concentrations, do not neutralize infection but
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potently promote ADE (Dejnirattisai et al., 2010). Consistent with these data, most of the
prM-specific mAbs described in the present study were highly cross-reactive and showed
ADE activity over a broad range of concentrations. The human studies together with
previous studies on mouse anti-prM mAbs that neutralize infection weakly, if at all, while
potently mediating ADE (Falconar, 1999; Henchal et al., 1985; Huang et al., 2006; Men et
al., 2004; Roehrig et al., 1998) suggest a potential role for this class of antibodies in
enhancing DENV infection in humans. Recent studies in infants have also implicated anti-
prM antibodies in the susceptibility of infants to severe dengue (Chau et al., 2009). It has
also been proposed that anti-prM antibodies could enhance DENV propagation by
enhancing the infectivity of immature, “non-infectious” virions (Rodenhuis-Zybert et al.,
2010). However, because the vast majority (>99%) of humans experiencing secondary
DENV infection do not develop severe life-threatening disease, the DI/DII-specific
antibodies or the less frequent highly neutralizing DIII-specific antibodies are likely
protective, along with other components of the innate and adaptive immune system.
The development of a vaccine against DENV has been problematic in part due to the
possible risk of eliciting suboptimal immune responses that might lead to ADE and severe
disease after infection with heterologous virulent strains. In the absence of an effective
DENV vaccine, passive immunotherapy with neutralizing antibodies may provide an
alternative for the treatment of dengue. A post-exposure prophylaxis approach is currently
being pursued for treatment of several viral diseases such as respiratory syncytial virus
(RSV), rabies, hepatitis B and WNV (Marasco and Sui, 2007). Humanized anti-DENV
mAbs obtained from mice or primates engineered with mutations that prevent binding to
FcR have been developed for this purpose (Balsitis et al., 2010; Goncalvez et al., 2007), but
fully human mAbs generated during a natural infection represent an attractive alternative
with a reduced antigenicity and risk of autoreactivity. Here, we selected three potent human
neutralizing mAbs as component of a cocktail capable of targeting two distinct epitopes on
each of the four DENV serotypes and engineered them with two leucine to alanine
mutations in the CH2 region that prevent binding to FcγR while preserving binding to the
neonatal FcRn (Hessell et al., 2007). The LALA variants retained neutralizing activity, and
when tested in vitro, failed to enhance DENV infection and inhibited enhancement elicited
by polyclonal immune sera or appropriate concentrations of intact antibodies. When tested
in vivo in a mouse model of lethal antibody-enhanced vascular leak syndrome, the LALA
mAbs protected against lethal infection induced by DENV-immune serum as a post-
exposure therapeutic. Even though effector functions can enhance protective efficacy of
anti-flavivirus antibodies (Chung et al., 2006; Mehlhop et al., 2009; Oliphant et al., 2005;
Schlesinger et al., 1993), they are not required for highly neutralizing antibodies. Thus, at
least in mice, even after ADE is initiated, there is a time window in which neutralizing
antibodies that lack the ability to enhance infection can still protect against lethal disease.
These results are a foundation for further investigation to address whether antibody-based
therapeutics can control severe DENV disease in humans.
Experimental Procedures
Memory B-cell immortalization and cloning
Peripheral blood samples were obtained from donors who had been diagnosed with DENV
infection. The study protocol was approved by the Scientific and Ethical Committee of the
Hospital for Tropical Diseases and the Oxford Tropical Research Ethical Committee. All
provided written informed consent. The determination of primary or secondary dengue was
made on the basis of acute serology and results of PRNT50 assays in late convalescence.
Peripheral blood mononuclear cells were isolated and cryopreserved. On the day of use,
PBMC were thawed and IgG+ memory B cells were enriched using CD22 microbeads
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(Miltenyi) followed by cell sorting as described (Traggiai et al., 2004). Cells were
immortalized at 20 cells/well in multiple cultures using EBV with CpG
oligodeoxynucleotide 2006 (Microsynth) and irradiated allogeneic PBMC. After 2 weeks the
culture supernatants were screened for the presence of DENV-specific mAbs and positive
cultures were cloned by limiting dilution.
Intracellular staining
C6/36 or Vero cells were infected with the DENV-3 recovered from Donor 76, with the
DENV-1 recovered from Donor 12, with DENV-2 WHO reference strain 516803, or with
DENV-1-4 vaccine strains at MOI leading to 70–90% of infected cells. After 5 days, cells
were harvested, fixed with 2% formaldehyde (Sigma), and permeabilized in PBS 1% FCS
0.5% saponin (Sigma). Cells were then incubated for 1h on ice with B cell culture
supernatants, washed and stained with Cy5-conjugated goat anti-human IgG (Jackson
Immunoresearch) and analyzed on a FACSArray (BD Biosciences).
ELISA
96-well ELISA plates were coated at 4°C with recombinant E protein from DENV-1-4 (Rey,
2003), with recombinant DIII from the DENV-3 of Donor 76 or with DIII of DENV-4
(Simonelli et al., 2010) (all at 1 µg/ml in 0.1M Na carbonate buffer, pH 9.3). After washing
and blocking, mAbs were added for 1h at 37°C. After further wash, mAbs bound were
revealed using goat anti-human IgG coupled to alkaline phosphatase (Jackson
Immunoresearch). In some experiments ELISA plates were coated with the 4G2 (1 µg/ml)
followed by a mixture of DENV-1-4 antigens.
Yeast expression and staining
Yeast expressing DI/DII and DIII of DENV-2 E protein were generated as previously
described (see Supplementary Experimental Procedures) (Oliphant et al., 2006; Sukupolvi-
Petty et al., 2007). Yeast cells expressing wild type or mutant DI/DII or DIII of DENV or
WNV (strain New York 1999) E protein were stained with mAbs on ice for 30 min. The
cells were then incubated with a goat anti-human IgG conjugated to Cy5 (Jackson
Immunoresearch) for 30 min on ice and analyzed by flow cytometry.
Immunoblot analysis
Equal amounts of concentrated supernatant from DENV-3- or DENV-2-infected or
uninfected Vero cells were separated under non-reducing conditions by SDS-PAGE and
transferred onto nitrocellulose membranes. Filters were blocked with 10% dry skim milk
and probed with mAbs. Blots were incubated with horseradish peroxidase–conjugated
mouse anti-human IgG, sheep anti-mouse IgG or donkey anti-rabbit IgG and developed with
ECL Plus Western Blotting Detection System (GE Healthcare). E protein was identified
using DV55.1, prM protein was identified using the mouse anti-prM mAb 2H2 (Falconar,
1999) and NS1 protein was identified using a rabbit anti-NS1 serum (Young et al., 2000).
The C protein was identified as a 16-kD band.
Production of recombinant IgG and LALA variants
RNA was isolated with RNeasy kit (Qiagen) from EBV-immortalized B cell clones
DV82.11, DV87.1, and DV22.3 and cDNA synthesized with M-MLV reverse transcriptase
(Invitrogen). Variable regions of heavy-chain and light-chain genes were sequenced and
cloned by PCR into human Igγ1, Igκ and Igλ expression vectors (provided by M.
Nussenzweig, Howard Hughes Medical Institute, The Rockefeller University, New York)
using gene-specific primers and Pfu Turbo (Stratagene) (Tiller et al., 2008). The vectors
contain a murine Ig gene signal peptide sequence and a multiple cloning site upstream of
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human Igγ1, Igκ and Igλ constant regions, with either wild-type or with leucine-to-alanine
mutations at positions CH2 1.3 and 1.2 of Igγ1, according to the IMGT unique numbering
for C-DOMAIN (LALA mutant) (Hessell et al., 2007) introduced by site-directed
mutagenesis (GenScript). Equal amounts of heavy and light chain vectors were mixed with
an equal amount of polyethylenimine (Sigma), incubated for 15 min and added to 80%
confluent HEK293T cells (ATCC) in DMEM supplemented with 1% Nutridoma (Roche).
Antibodies were recovered from supernatants harvested 3 days after transfection and
purified using protein A affinity chromatography followed by Sephadex 200 size-exclusion
chromatography.
Infection neutralization and enhancement
DENV neutralization was measured using a flow based assay. The day before the infection,
5,000 Vero cells were plated in 96-well flat-bottom plates. Different dilutions of mAb were
mixed with DENV (all at MOI of 0.04) for 1h at 37°C and then added to Vero cells. After
three days the cells were fixed with 2% formaldehyde, permeabilized in PBS 1% FCS 0.5%
saponin, and stained with 4G2. The cells were incubated with a goat anti-mouse IgG
conjugated to R-phycoerythrin (Southern Biotechnology) and analyzed by flow cytometry.
EC50 values were determined by nonlinear regression analysis. ADE was measured by a
flow assay using K562 cells. mAbs and DENV (MOI of 0.04) were mixed for 1 hour at
37°C and added to 5000 K562/well. After three days, cells were fixed, permeabilized, and
stained with 4G2 and the number of infected cells was determined by flow cytometry as
above.
Effect of LALA antibodies on ADE
Potent enhancing antibodies (0.1 µg/ml) or serum from primary dengue-infected donors
were mixed with an equal volume of LALA cocktail (DV82.11 =2 µg/ml;
DV87.1=DV22.3= 0.2 µg/ml). Attenuated DENV-1-4 virus strains (MOI of 0.04) and the
antibody were mixed, added to K562 cells, and incubated for three days. Cells were stained
with 4G2 and analyzed by flow cytometry as describe above.
Infection of AG129 mice
129/Sv mice lacking the interferon α/β and γ receptors (AG129) (van den Broek et al., 1995)
were bred in the University of California, Berkeley Animal Facility. All experimental
procedures were pre-approved by the University of California Berkeley Animal Care and
Use Committee (ACUC) and were performed according to the guidelines of the UC
Berkeley ACUC. Mice were injected i.p. with mAb, PBS, or anti-DENV sera in a total
volume of 200 µl, then infected 18–24 hours later with either 105 or 106 pfu of DENV strain
D2S10 diluted in 100µl volume by intravenous (i.v.) injection into the tail vein. In some
experiments, 50 µg of mAb were transferred to mice i.v. 24 hours post-infection to assess
the therapeutic efficacy of the mAb.
Statistical analysis
Mortality data were expressed using Kaplan-Meier survival curves, and log-rank analyses
were used to determine statistical significance using Prism (GraphPad software). Viral load
values for different tissues were compared between experimental groups using a two-sample
Wilcoxon rank-sum analysis (Stata v10, College Station, Texas).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Specificity and function of human mAbs against DENV
(A) Vero cells, uninfected or infected by DENV-1, −2, −3, and −4 vaccine strains, were
fixed, permeabilized, and stained with human mAbs, followed by fluorescently-labeled anti-
human IgG polyclonal antibodies. Representative dot plots show staining by mAbs isolated
from Donor 76 reactive against DENV-3 alone (DV79.3), DENV-1 and DENV-3 (DV63.1)
or cross-reactive against the four DENV serotypes (DV82.11, DV69.6, DV59.3). Numbers
in quadrants indicate the percentage of positive cells. The data shown are for five mAbs and
are representative of data obtained with 70 DENV-reactive mAbs and of at least two
independent experiments. (B–D) Western blot analysis of mAbs that were not reactive by
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ELISA. Concentrated supernatants of uninfected control (−) or DENV-3-infected Vero cells
(+) were separated under non-reducing conditions. B) E- and capsid-specific mAbs. E
protein was identified by DV55.1, a mAb specific for E protein in ELISA. Capsid migrate
with apparent molecular weights of 16 kD. C) shows prM-specific mAbs. PrM protein was
identified by the mouse anti-prM mAb 2H2. D) shows NS1-specific mAbs. NS1 protein was
identified by a rabbit anti-NS1 serum. The data are representative of at least two
independent experiments. (E) Examples of viral neutralization assay in which serial
dilutions of mAbs (DV63.1 and DV5.1) were incubated with DENV-1-4 before addition to
Vero cells. Shown is the percentage of infected cells after 3 days as a function of increasing
mAb concentration. Nonlinear regression analysis was used to calculate the EC50, values
indicated in the panel. (F) Infection enhancement assay in which serial mAb dilutions were
incubated with DENV-1-4 before addition to K562 cells. Shown is the percentage of
infected K562 cells. The range of mAb concentrations where infection enhancement was
observed is indicated in gray. Numbers in the gray areas represent logarithm power. The
data shown are from one representative experiment out of three independent experiments
performed. Data obtained with the panel of DENV-reactive mAbs are shown in Tables 2, 3
and 4.
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Figure 2. Three mAbs neutralize all four DENV serotypes by binding two distinct epitopes on
each virus
Three mAbs (all IgG1) were selected for their specificity and neutralizing activity: DV87.1
binds DIII of DENV-1, −2 and −3; DV22.3 binds DI/DII of DENV-4, and DV82.11 cross-
reacts with DI/DII of all DENV serotypes. (A) Neutralization (○) and enhancement (●) of
infection by recombinant unmodified mAbs. (B) Neutralization (○) and enhancement (●) of
infection by engineered LALA variant mAbs. Nonlinear regression analysis was used to
calculate the EC50, indicated in the panel. Data are mean of duplicates. One representative
experiment out of three performed. (C) A cocktail of LALA-mAbs (DV82.11= 2 µg/ml,
DV87.1=DV22.3= 0.2 µg/ml) was used in combination with mAbs directed against prM
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(DV69.6) or DI/DII E protein (DV78.6) or serum from a primary DENV-infected donor at
potent enhancing concentration (0.1 µg/ml) on K562 cells. Numbers in quadrants indicate
the percentage of infected cells, as revealed by staining with an anti-E mouse mAb. The data
shown are from one experiment representative of two performed. See also Figure S1 and
Table S2.
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Figure 3. LALA variants do not enhance DENV in vivo and demonstrate post-exposure
therapeutic efficacy
A (Top). 1 or 5 µg of DV87.1, DV87.1 LALA variant, 4G2 or PBS were transferred i.p. in
200 µl volume into AG129 mice (n = 3 per group). The mice were infected 18–24 h later
with 106 pfu DENV-2 strain D2S10. (Bottom). 1 or 5 mg of DV82.11, DV82.11 LALA
variant, 4G2 or PBS were transferred i.p. in 200 µl volume into AG129 mice (n=3 per
group). The mice were subsequently infected 18 to 24 h later with 106 pfu DENV-2 D2S10.
All mice receiving LALA-variant mAbs survived as compared to mice receiving a lethal,
antibody-enhanced infection (1 or 5 µg DV87.1 LALA, p< 0.0253; 1 or 5 µg DV82.11
LALA, p< 0.0455 compared to 4G2 mAb positive control). (B) AG129 mice were
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administered 35 µl anti-DENV-1 serum i.p. and were infected 24 h later with 105 pfu of
DENV-2 D2S10 i.v.. Twenty-four h after infection, the mice were treated with 50 µg of
either DV87.1, n=6; DV87.1 LALA, n=6; DV82.11, n=6; DV82.11 LALA, n=5; DV22.3
LALA, n=6; or PBS, n=6 i.p.. In all cases, mortality was monitored daily for ten days. Mice
treated with either 50 µg DV87.1 LALA (p<0.0015) or DV82.11 LALA (p<0.011) 24 h
post-infection survived significantly longer than mice receiving 50 µg of non-binding LALA
variant mAb DV22.3. See also Figure S2.
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